ABBV ABBV アッヴィ

 ABBVのチャート


 ABBVの企業情報

symbol ABBV
会社名 AbbVie Inc (ABBV アッヴィ)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 アッヴィ(AbbVie Inc.)は研究型バイオ医薬品会社である。同社は各種医薬品の発見・開発・製造・販売に従事する。同社の製品はリウマチ学、胃腸病学と皮膚科学等の慢性自己免疫疾患、血液癌を含む腫瘍学、C型肝炎ウイルス(HCV)とヒト免疫不全ウイルス(HIV)を含むウイルス学、パーキンソン病と多発性硬化症等の神経学的障害、甲状腺疾患と嚢胞性線維症関連合併症を含む代謝性疾患、並びに他の健康状態の治療のために使用される。同社はHUMIRA(アダリムマブ)、腫瘍学製品、ウイルス学、追加のウイルス学製品、代謝またはホルモン製品、内分泌学製品、並びにDuopaおよびDuodopa(カルビドパおよびレボドパ)、麻酔薬およびZINBRYTA(ダクリズマブ)を含む他の製品を提供する。  アッヴィは米国の研究開発型バイオ医薬品企業。主にC型肝炎、神経学、免疫学、腫瘍学、慢性腎疾患および女性の疾患などの分野における医薬品の開発に取り組む。アボット・ラボラトリ―ズの研究開発医薬品部門の分離独立に伴い2013年度に設立。主力製品はリウマチ性関節炎や乾癬治療薬「ヒュミラ」など。本社はイリノイ州ノ―ス・シカゴ。  
本社所在地 847 932-7900
代表者氏名 Richard A. Gonzalez
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 847-932-7900
設立年月日 41000
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 30000人
url www.abbvie.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 9148.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 119125.30000
売上高 売上高(百万ドル) 32753.00000
企業価値(EV) 企業価値(EV)(百万ドル) 151374.30000
当期純利益 当期純利益(百万ドル) 5743.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 AbbVie Inc revenues increased 16% to $32.75B. Net income applicable to common stockholders excluding extraordinary items increased 1% to $5.74B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Research and development - Balanci increase from $4.82B to $10.16B (expense) Selling.

 ABBVのテクニカル分析


 ABBVのニュース

   Imbruvica Market Worth Observing Growth | AbbVie, Johnson and Johnson, SP Laboratories  2021/01/15 14:14:28 OpenPR
Latest added Global Imbruvica Market research study by HTF MI offers detailed product outlook and elaborates market review till 2025. The market Study is segmented by key regions that is accelerating the marketization. At present, the market is sharping its
   FXNEWS24 |AbbVie (ABBV) Inks Deal to Acquire Medical Device Company | UK Forex Reviews  2021/01/13 16:38:16 FXNews24
AbbVie (ABBV) Inks Deal to Acquire Medical Device Company | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations  2021/01/13 12:25:38 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) AbbVie Inc (NYSE: ABBV ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) AtriCure Inc. (NASDAQ: ATRC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BIOLASE Inc (NASDAQ: BIOL ) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) CareDx Inc (NASDAQ: CDNA ) Celsius Holdings, Inc. (NASDAQ: CELH ) DermTech Inc (NASDAQ: DMTK ) Dyne Therapeutics Inc (NASDAQ: DYN ) Edap Tms SA (NASDAQ: EDAP ) Evelo Biosciences Inc (NASDAQ: EVLO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Eyenovia Inc (NASDAQ: EYEN ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Guardant Health Inc (NASDAQ: GH ) (reacted to presentation at the JPMorgan Healthcare Conference) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Laboratory Corp.
   RBC Capital Stick to Their Buy Rating for AbbVie By Investing.com  2021/01/13 01:58:22 Investing.com
RBC Capital Stick to Their Buy Rating for AbbVie
   Allergan Aesthetics Enters Into Option to Acquire Cypris Medical  2021/01/12 21:05:00 PR Newswire
IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to…
   Pharmaceutical Contract Development & Manufacturing Market 2020-2027: Size, Share, Growth, Trends with Key Players Analysis- AbbVie, Almac Group, Catalent, Evonik, Lonza, Recipharm AB, Siegfried AG, The Aenova Group, Thermo Fisher Scientific, Vetter etc.  2021/01/07 15:16:51 OpenPR
A new market report by The Insight Partners on the Laboratory Informatics Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of
   AbbVie Is Mizuho’s Top Pick Among Large-Cap Biopharma Stocks  2021/01/07 13:45:00 Barron's
Mizuho analyst Vamil Divan said he is bullish about the sector, citing continued innovation, a favorable environment in Washington, and the potential for continued M&A.
   Patent Medicine Market With Leading Players like Pfizer, Otsuka Pharmaceutical Co., Ltd. GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc. Roche Holding AG, Amgen, AbbVie, Sanofi, Bristol-Myers Squibb Company  2021/01/07 05:53:56 OpenPR
An off-the-shelf report on Patent Medicine Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such as
   Pharma firms ring in 2021 by hiking prices for hundreds of drugs  2021/01/05 20:17:09 New York Post
Nothing says “happy new year” like pricier prescriptions. Drugmakers have already raised list prices on more than 500 drugs in the US in the first days of 2021, researchers say. Dozens of pharmaceutical firms including Pfizer, Abbvie, AstraZeneca and Bristol Myers Squibb started imposing the hikes on Jan. 1, according to data compiled by health-care…
   AbbVie Is a Stock to Position for 2021  2021/01/05 15:30:00 The Street RealMoney
Let's review the charts and indicators….ABBV
   Protein Therapeutics Market 2020-2024- Featuring AbbVie Inc., Amgen Inc., AstraZeneca Plc, Among Others to Contribute to the Market Growth | Industry Analysis, Market Trends, Opportunities, and Forecast 2024 | Technavio  2020/12/03 12:45:00 Business Wire
LONDON--(BUSINESS WIRE)-- #GlobalProteinTherapeuticsMarket--The Protein Therapeutics Market will grow by USD 82.47 bn during 2020-2024
   CVS, Rite Aid join pay-for-delay litigation over AbbVie's Bystolic  2020/12/02 23:35:34 Reuters
CVS Pharmacy Inc and Rite Aid Corp have sued AbbVie Inc and several generic drugmakers over an alleged scheme to keep generic versions of AbbVie's blood pressure drug Bystolic off the market through anticompetitive "pay-for-delay" settlements.
   Specialty Pharmaceuticals Market Current Trends And Efficient Techniques, Forecast 2027|| Teva Pharmaceuticals, Abbvie, Amgen, Johnson & Johnson, Celgene, Gilead Sciences, Roche  2020/12/02 18:43:39 OpenPR
An extensive overview of the Specialty pharmaceuticals Market is recently added by SMI to its enormous database. The report offers a detailed analysis of the latest industry developments, technologies, and trending factors in the market that are influencing the market
   AbbVie eyes cancer, immunology in latest protein degradation pact, handing Frontier Medicines $55M upfront  2020/12/02 15:52:17 Endpoints News
Two years after tiptoeing into the protein degradation space with a discovery pact centered on neurodegeneration, AbbVie is wading deeper to explore the more common applications in cancer and immunological diseases. The pharma giant is handing Frontier Medicines $55 million upfront to get things started while promising to reimburse its
   Global Biologics Market Incredible Possibilities, Growth Analysis And Forecast To 2027||Key Players-Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson Services Inc  2020/12/02 15:04:41 OpenPR
Data Bridge Market research released a new market study on Biologics with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis In Biologics research report also directs the manufacturer about

 関連キーワード  (医薬品 米国株 ABBV アッヴィ ABBV )

 twitter  (公式ツイッターやCEOツイッターなど)